Back to results
US 2022/0356153 A1Published application
Compositions for treating neurodegenerative diseases
AssigneeCognition Therapeutics, Inc.
InventorsGilbert M. RISHTON, Gary C. LOOK, Susan M. CATALANO
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to novel compounds, pharmaceutical compositions containing the compounds and methods of using the compounds and pharmaceutical compositions for treating neurodegerative diseases, including Alzheimer's disease and cognitive decline. Methods for inhibiting synapse number decline or membrane trafficking abnormalities associated with exposure of a neuronal cell to Abeta species are also disclosed.
Claims9
1-27. (canceled)
A compound of Formula I or pharmaceutically acceptable salt thereof:
- wherein:
- each of Ra, Rb, Rc, Rd and Re is independently selected from the group consisting of H, hydroxyl, halo, alkyl, alkoxy, CF3, SO2CH3, and morpholino;
- R1 is selected from the group consisting of hydrogen, alkyl, phenyl, or —CH═C(CH3)2;
- and
- R2 is a substituted cyclic amino group, which is:
- (a) selected from the group consisting of:
- wherein R3a selected from the group consisting of hydrogen and C1-C8 alkyl;
- and n is an integer selected from 0, 1 and 2;
- or
- (b) selected from the group consisting of:
- or
- (c) selected from the group consisting of:
- wherein R9 is independently selected from the group consisting of hydrogen, hydroxyl, sulfonyl, optionally substituted C1-C10 alkyl, optionally substituted C5-C10 aryl, optionally substituted C5-C10 heteroaryl, optionally substituted C3-C10 cycloalkyl and optionally substituted C3-C10 heterocycloalkyl.
10 more elements
Dependencies are inferred from the claim text.